Day 7 serum TGF-β1 and CTGF levels exhibited high sensitivity and specificity for differentiating lung damage in COVID-19 patients (sensitivity, 96%; specificity, 89% for TGF-β1; sensitivity, 94%; and specificity, 91% for CTGF). This evidence concerns the gene CCN2 and COVID-19.